Committed to Helping Enable Patient Access and Minimize Barriers to DUPIXENT

1‑844‑DUPIXEN(T)

DUPIXENT MyWay is a support program that can help optimize access to DUPIXENT and provides:

To enroll in DUPIXENT MyWay your patients can call 1‑844‑DUPIXEN(T).

Coverage and Access Support for Eligible Patients

Coverage Support

Provides guidance and assistance navigating through the insurance process.

Download a complete guide and sample letters regarding coverage for DUPIXENT:

1.2MbNavigating PAs and Appeals for
DUPIXENT


Benefits Investigation, prior authorizations (PAs), and appeals support
DUPIXENT MyWay verifies your patient’s specific health plan coverage for DUPIXENT, as well as copay information. If a PA is required, your DUPIXENT MyWay Coordinator can help you navigate the PA process. They will also help you and your patients understand the appeal process if coverage is denied and provide education about the process.


Patient assistance program
DUPIXENT MyWay can help assist eligible uninsured or functionally uninsured patients. Patients will need to meet the eligibility criteria, including household income, to qualify. The DUPIXENT MyWay team will research each patient’s situation and determine if he or she is eligible.

Nursing Support

A patient-centric approach to educating and empowering patients to use and stay on DUPIXENT as prescribed.

Every enrolled patient is assigned a dedicated phone‑based DUPIXENT MyWay Nurse Educator. Within one business day after receiving a completed and signed enrollment form, the Nurse Educator will contact your patient to introduce the program.


The Nurse Educator will provide benefit information as soon as the benefits investigation is complete and will help the patient through the process of getting started on DUPIXENT.


Ongoing follow‑up and education about DUPIXENT are provided by the Nurse Educator to help patients stay on track with DUPIXENT.


Supplemental injection training helps patients get comfortable injecting themselves.

Patient Access Support

$0 copay carda helps optimize access to DUPIXENT treatment.

With the DUPIXENT MyWay Copay Card, eligible patients may pay as little as $0 for every month of DUPIXENT.


Eligibility Requirements:
  • Commercially insured
  • Patient resides in the 50 United States, the District of Columbia, or Puerto Rico
  • Patient has a valid prescription for DUPIXENT for an approved indication

Eligible patients can sign up for a DUPIXENT MyWay Copay Card that may help cover the cost of DUPIXENT. Send them the following links to register.

Patients aged 12‑17

Patients aged 18+


a Eligible patients with commercial insurance (not funded through a government healthcare program such as Medicare or a similar program) and subject to program restrictions, including a maximum of $13,000 per calendar year.

Questions About the Insurance Process?

Our team will provide guidance and assistance during the insurance approval process. If your patients need further support, DUPIXENT MyWay Nursing Support is available 24/7 as a dedicated, single point of contact.

Conducts a benefits investigation

  • Verifies patients’ health plan coverage
  • Determines a plan’s utilization management criteria
  • Identifies patients’ out‑of‑pocket responsibilities

Provides PA support

  • Educates HCPs and staff to ensure appropriate information and forms are submitted

Educates about the appeals process

  • Educates staff about appropriate actions needed to appeal any coverage denial

92% of commercial adult patients nationally are covered with 63% of commercial lives requiring 1 or 2 prescription topical step edits1,b

1

Prescribe DUPIXENT.

2

Submit the DUPIXENT MyWay enrollment form.

3

DUPIXENT MyWay completes a benefits investigation, and determines if there are any requirements for PA, for DUPIXENT. Submit a Letter of Medical Necessity and include all required documentation (eg, a copy of your chart notes with details of diagnosis, disease severity, and treatment history).

4

Receive a status update from your DUPIXENT MyWay coordinator.

Approval

DUPIXENT MyWay representative arranges shipment via specialty pharmacy (in network) or patient arranges shipment with specialty pharmacy (out of network).

Appeals

If a PA is denied, you can fill out an appeal form, write an appeal letter, and add supporting documentation.

Sample Lettersc:

b Data as of Q1 2019.

Connect With a Rep Have questions about DUPIXENT? Get
answers from a representative.
Request a Visit
Dosing and Administration Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Frequently Asked
Questions
Have questions? Get answers to some of
the most commonly asked questions.
Get Answers
Reference:
References:
  1. DUPIXENT Prescribing Information. March 2019.
  2. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  3. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  4. Data on file, Regeneron Pharmaceuticals, Inc.
  5. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of Th2/Th22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012:130(6):1344-1354.
  6. DUPIXENT Prescribing Information. March 2019.
  7. Wei W, Anderson P, Gadhari A, et al. Extent and consequences of inadequate disease control among adults with atopic dermatitis. J Dermatol. 2018;45(2):150-157.
  8. DUPIXENT Prescribing Information. March 2019.
  9. DUPIXENT Prescribing Information. March 2019.
  10. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M; the EASI Evaluator Group. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11-18.
  11. Data on file, Regeneron Pharmaceuticals, Inc.
  12. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebocontrolled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  13. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  14. EASI User Guide. HOME-Harmonising Outcome Measures for Eczema website. Http://www.homeforeczema.org/documents/easi-user-guide-jan-2017-v3.pdf. Accessed January 4, 2019.
  15. DUPIXENT Prescribing Information. March 2019.
  16. Data on file, Regeneron Pharmaceuticals, Inc.
  17. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderateto-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  18. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  19. DUPIXENT Prescribing Information. March 2019.
  20. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  21. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-507.
  22. Data on file, Regeneron Pharmaceuticals, Inc.
  23. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  24. DUPIXENT Prescribing Information. March 2019.
  25. Data on file, Regeneron Pharmaceuticals, Inc.
  26. DUPIXENT Prescribing Information. March 2019.
  27. Data on file, Regeneron Pharmaceuticals, Inc.
  28. DUPIXENT Prescribing Information. March 2019.
  29. Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderateto-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519-1531.
  30. DUPIXENT Prescribing Information. March 2019.
  31. Data on file. Regeneron Pharmaceuticals, Inc.
  32. DUPIXENT Prescribing Information. March 2019.
  33. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  34. Data on file, Regeneron Pharmaceuticals, Inc.
  35. DUPIXENT Prescribing Information. March 2019.
  36. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of Th2/Th22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354.
  37. DUPIXENT Prescribing Information. March 2019.
  38. DUPIXENT Prescribing Information. March 2019.
  39. Data on file, Regeneron Pharmaceuticals, Inc.